Background: The aim of this review is to present the available clinical and surrogate endpoints that may be used in future studies performed in patients with peripheral artery occlusive disease (PAOD). Importantly, we describe statistical limitations of the most commonly used endpoints and offer some guidance with respect to study design for a given sample size. The proposed endpoints may be used in studies using surgical or interventional revascularization and/or drug treatments.
INTRODUCTION
Peripheral artery occlusive disease (PAOD) is a manifestation of systemic atherosclerosis in the lower extremities and is associated with a significant mortality and morbidity, especially in the elderly. [1] [2] [3] It is of paramount importance that patients with intermittent claudication (IC) and critical limb ischemia (CLI) be recognized as different populations that should be studied separately. 4 While there are a number of available diagnostic tools such as computed tomography angiography (CTA), magnetic resonance angiography (MRA), ultrasound Doppler or duplex Doppler (USD), and digital subtraction angiography (DSA), other markers are also available that gauge the severity of PAOD.
Before presenting individual endpoints, one should mention that there are initiatives to standardize study endpoints as ambiguous definitions do not permit inter-study comparisons among peripheral endovascular studies. [4] [5] Fleming and Powers describe a relevant primary endpoint as a measure of how the patient "feels, functions and survives". [6] [7] In this context, survival rate, disease exacerbation or absence of clinical events, and subjective health quality are viewed as pertinent indicators of clinical success. The most commonly used measure of treatment success in the peripheral vascular bed are patency, occlusion rates 8 , and target lesion revasularization 9 (TLR) rates. Even though the ankle-brachial index 2, 10 (ABI) is mostly used as a variable for stratification or risk classification, it could potentially be used as a primary endpoint as well. The list of meaningful surrogate endpoints includes walking distance 11 (WD) that may be defined as maximum walking distance (MWD) or pain-free walking distance (PFWD). Recently, transcutaneous oxygen tension measurements (TcPO 2 ) in revascularized tissues 12 , and more specifically in patients with CLI 13 , have also been considered as potential endpoints. Moreover, in patients with advanced PAOD with Rutherford class 6, amputation 14 or mortality rates 2 as well as wound healing surrogate endpoints 15 , such as wound area post-revascularization, may serve as pertinent study endpoints. Quality of life endpoints have also been used to assess treatment success in patients with IC in RCTs. 16 
METHODS
We hypothesize that there are differences in required patient numbers for endpoints of equal clinical importance. The purpose of this review is to describe, evaluate, and compare potential primary study endpoints for PAOD trials in terms of their clinical value, reimbursement relevance, and corresponding study sample sizes that ensure sufficient statistical power.
Furthermore, we hypothesize that there are reimbursement-relevant endpoints that can be chosen for future studies without the need to use large sample sizes. To better explain these complex relationships, a graphic comparison is attempted to gauge the given endpoints and their clinical/reimbursement value based on a semi-quantitative scoring system.
original article H o : LLL 1 in the treatment group is equal to or higher than the LLL 2 in the control group H a : LLL 1 in treatment group is lower than the LLL 2 in the control group
Angiographic endpoint /non-inferiority
The non-inferiority test hypothesis in terms LLL can be expressed as:
H o : LLL 1 in the treatment group minus the LLL 2 in the control group is larger than or equal to a non-inferiority margin Δ LLL H a : LLL 1 in the treatment group minus the LLL 2 in the control group is smaller than a non-inferiority margin Δ LLL
Surrogate endpoint ankle brachial index (ABI)/ test for difference
Positive changes in the hemodynamic environment, i.e. lower pressure drop across a target lesion, can be assessed with the ankle brachial index (ABI). The most feasible statistical approach is to observe post-interventional/post-surgical ABIs in two treatment groups (superiority design) or ABIs in one treatment group Because of its high relevance, comprehensiveness, and a recent publication date, the systematic review by Simpson et al. 17 was used to select PAOD-related study endpoints to estimate the number of patients required by particular study designs. Simpson and coworkers included patency, restenosis measures, need for re-intervention, generic measures of quality of life (QoL), clinical status, exercise tolerance, walking distance, limb salvage, complications, and adverse events as relevant study endpoints.
STATISTICAL ANALYSIS
The numbers of patients required per study design were estimated with nQuery/nTerim, version 2.0 (Statistical Solutions Ltd. Cork, Ireland). Depending on the dependent variables (dichotomous, continuous), various biometric algorithms were used. The tested hypotheses were divided in terms of clinical/surrogate endpoints and non-inferiority and superiority designs (test for difference).
ENDPOINT DESIGNS

Dichotomous event rates
The most common dichotomous event rate is the patency rate (primary, primary assisted, or secondary) which can also be interpreted as 100% patency rate minus the occlusion rate. As defined by Diehm et al. [4] [5] , patency should not be interpreted as a non-occlusion rate but rather as freedom from binary restenosis, i.e. diameter stenosis of less than 50% either measured by quantitative angiography or by ultrasound. Other dichotomous event rates can be amputation or infection rates, which may not be the first choice in the general PAOD population.
Common designs to show a significantly better patency rate are described with the following test hypotheses:
H o : Patency rate π 1 in the treatment group is lower than or equal to the patency rate π 2 in the control group H a : Patency rate π 1 in the treatment group is higher than the patency rate π 2 in the control group A non-inferiority test hypothesis is formulated as follows:
The patency rate π 2 in the control group minus the patency rate π 1 in the treatment group is larger than or equal to the non-inferiority margin Δ.
H a : The patency rate π 2 in the control group minus the patency rate π 1 in the treatment group is smaller than the non-inferiority margin Δ.
ANGIOGRAPHIC ENDPOINT/ TEST FOR DIFFERENCE
Differences in interventional treatment groups are often described with late lumen loss (LLL) either in-lesion or in-segment, which are obtained from baseline and follow-up angiograms at a pre-specified post-procedural time point. a range of binary restenosis rates in both treatment groups (top panel) and sample size estimates for a non-inferiority design with different noninferiority margins, a higher binary restenosis rate in the control group (by 4%), and expected differences in binary restenosis rates (bottom panel).
Fig. 2.
Sample size estimates for a non-inferiority design with different noninferiority margins (3.0%-1.0%), a 5.0% amputation rate in the control group and different expected amputation rates in the treatment group (to be defined in minor, major, BTK, and ATK). A common clinical endpoint in patients with advanced Rutherford categories (4-6) or CLI is the amputation rate. This endpoint, in turn, can also be included in a composite endpoint such as major adverse limb events (MALE). When limb salvage is of primary interest, a non-inferiority design (see Figure 2 ) with an amputation rate of 5.0% in the control group, 4.0% in the treatment group, and a non-inferiority margin of only 1.0% will require 1686 patients per group to reject the null hypothesis (one sided α=2.5%, power=80%).
The numbers of patients in a trial with Rutherford category shift as the primary endpoint are illustrated in Figure 3 . Expected ranges can be obtained from a DCB study that was conducted by Scheinert and coworkers. 18 In this case, the difference in Rutherford categories at follow-up as compared to the post-interventional Rutherford categories are used as an efficacy marker. The 3D curve in Figure 3 has a flat appearance for most of the assumed Rutherford category shift, up to an expected difference of 0.22 in the treatment group. Conversely, large patient numbers are necessary if the expected difference in Rutherford category shift is lower than 0.22 in the treatment group.
While patency, occlusion, and binary restenosis rates are the most commonly used endpoints in studies with surgical revascularization H a : TcPO 2 at time point t n is higher as compared to TcPO 2 at time point t n-1 where t n is the time point after t n-1 .
Rutherford category shift endpoint/ test for difference
The Rutherford category shift entails that 7 different Rutherford categories (0=no claudication to 6=severe limb ischemia with tissue loss) are translated into a set of ordinal data. When comparing two time points (e.g. pre-treatment vs. follow-up), the signed-rank test may be considered:
H o : There is no improvement in the Rutherford categories between the post-treatment condition and at the follow-up H a : Rutherford categories improve at the follow-up interval as compared to the baseline condition.
Quality of life endpoint/ test for difference
Patients' responses on quality-of-life (QOL) questionnaires must be transferred to a score either per treatment group or in one treatment group at various time points. This may be translated into the following test hypotheses:
The QOL treatment score in the treatment group is equal to or lower than that in the control group H a : The QOL treatment in treatment group is higher than the QOL control score in the control group Tables 1 to 4 summarize the most commonly used endpoints which correspond directly or indirectly to the clinical outcomes measures proposed by Simpson et al. 17 These endpoints, with their respective advantages and disadvantages, are listed in the aforementioned tables. For selected endpoints, the required patient numbers per treatment group with a significance level α and a power of 80% were calculated.
RESULTS
The most commonly used endpoints in the general PAOD population are patency and restenosis rates 17 since they are directly related to treatment efficacy. In vascular reconstructions, patency is typically defined as 100% minus the occlusion rate, whereas in the endovascular studies the binary restenosis (BR) rate, most commonly defined as a 50% diameter loss, seems to be used most commonly. Figure 1 displays patient population sizes for various BR rate assumptions in the treatment and the control groups. Naturally, the smaller is the expected difference in BR rates, the larger will be the required number of patients per group. For instance, if we assume a BR rate of 30.0% in the control group and 20.0% in the treatment group, we would require 313 patients per group (one-sided α=2.5%, power=80%). Alternatively, assuming a non-inferiority design with an BR rate of 20.0% in the control group, an expected BR rate in the treatment group of 16.0%, and a non-inferiority margin of 4.0%, a total of 362 patients per group (one-sided α=2.5%, power=80%) would be needed (Figure 1) . Overall, with a double digit difference between two event rates, several hundred subjects would be needed per group to reject the null hypothesis, i.e. a benefit in the treatment group. setting. ABI is a ratio of systolic blood pressure in the dorsalis pedis or posterior tibial arteries to the highest systolic blood pressure value measured on the left or right arm. 20 In this scenario, ABI of less than 0.9 is considered to be the threshold value 21 for further diagnostic explorations. Assuming ABI standard deviation for both groups of 0.125 and expected mean ABIs in the treatment group of 1.00 and 0.95 in the control group, each group must have 100 patients.
For the pain-free walking distance and the maximum walking distance, biometric estimates based on a superiority design (test for difference) are illustrated in Figure 5 . Assuming a walking distance (WD) of 350 m in the treatment group and 275 m in the control group with a common standard deviation of 150 m, derived from the literature 22 , 64 patients per group or 128 patients in total would be required to reject the null hypothesis of no difference between both study groups (one sided α=2.5%, power=80%).
Below the knee (BTK) clinical studies are mostly concerned with limb salvage and potentially ulcer healing; thus, measurement of transcutaneous oxygen tension (TcPO 2 ) may be a clinically relevant surrogate endpoint in such studies. Redlich et al. 12 documented pre-treatment TcPO 2 values of 20.5 ± 4.8 mmHg in diabetic patients techniques, angiographic endpoints (Table 2 ) seem to be favored in studies in interventional radiology. Late lumen loss (LLL), i.e. the loss of lumen diameter at follow-up (typically at 6-8 months) relative to the post-intervention time point, necessitates a blinded core lab. In principle, quantitative angiography analyzes shadow images of contrast-filled arterial segments using edge detection algorithms. LLL is the difference between the minimal lumen diameters (MLD) which are measured in the post-procedural and the follow-up angiograms. Based on MLDs, other angiographic endpoints, such as percent stenosis, can be calculated. For an expected LLL of 0.4 mm in the treatment and 0.6 mm in the control group (Figure 4) , a total of 194 subjects would be required assuming a LLL standard deviation of 0.7 mm for both groups (power=80%, one-sided alpha=0.025). Mean lumen diameters, i.e. the averaged lumen diameter along a stenotic segment, can also be calculated from angiographic images. Provided that a comparison with an un-diseased vessel segment is possible 19 , intra-patient controls may serve as an alternative when a control group is not feasible. This approach also permits the use of a paired t-test (intra-patient comparisons), which may add statistical power. Table 3 summarizes potential surrogate endpoints, such as the ankle brachial index (ABI), which can be readily measured in a non-clinical perspective. ABI measurements in target legs, when compared to non-target legs, appear useful to estimate treatment effects. Nevertheless, target and non-target legs must be functioning in the same patient to produce meaningful data for a QOL-relevant walking distance assessment. Major amputations have an important impact on the patients' QOL, especially in the case of CLI. Consequently, major amputation rates are highly relevant from a reimbursement point of view (RRV=90%) since they are associated with a high cost. 27 An attempt to illustrate these complex relationships in patients with PAOD is presented in Figure 9 . When focusing on the most striking difference, it is obvious that the endpoints of walking distance and ABI have a high reimbursement impact and a moderate demand for sample size. In contrast, MLD has a low reimbursement value despite a moderate size of the required sample. Studies with the primary endpoint of amputation rate have a high reimbursement value but require a large number of patients.
DISCUSSION
To our knowledge, this is the first attempt to provide an overview of patient sample sizes for the most common endpoints used in PAOD-related studies. The most commonly used questionnaire of quality of life is the EuroQuol-5D with either 3 or five levels of responses to five questions regarding mobility, self-care, usual activities, pain/discomfort, and anxiety/depression. In addition, this patient self-assessment tool includes an estimate, on a scale of 0 to 100, of how the patient sees their health status (100=best health status). This questionnaire needs validation on a country specific level, e.g. a German patient would probably be slightly more critical to specify his overall health status as compared to a patient from the South of France.
For simplicity, the sample size calculations for quality-of-life assessments are based on the SF-36 scoring system for which a pretreatment baseline value of approximately 40 can be assumed for patients with CLI.
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Assuming post-treatment scores between 50 and 65 and identical standard deviations of 5.0-15.0 for both groups, the number of subjects can range between less than 10 and 100 per group.
A potentially useful semi-quantitative methodology (reimbursement scoring system) that illustrates the relative reimbursement value (RRV) for various study endpoints and their corresponding population sizes was first introduced in the field of interventional cardiology. 23 This approach can also be proposed for PAOD-related studies (Figure 9 ). The number of patients for a superiority test hypothesis, e.g., for MLD and LLL, can be displayed in terms of the reimbursement value. The required study sample would be in the range of 25-200 patients (see Figure 4) . However, the reimbursement value for angiographic endpoints in PAOD-related studies would be rather low since they are not used in health technology assessments. 17 An analogous non-inferiority test hypothesis in terms of amputation rates would require 200-1600 patients (Figure 2 ). In principle, clinical efficacy corresponds to the reimbursement value. In this regard, a cause-effect relationship between the clinical parameter and quality of life (QOL) must be established. A relative reimbursement value (RRV) of 100% means that there is a direct impact of the measured endpoint on QOL. This can be illustrated with the size of a bubble (Figure 9 ). In our opinion, the reimbursement value for patients with PAOD is directly related to the patients' mobility, which can be measured with the walking distance to accomplish daily chores (RRV=80%). 24 A Rutherford category shift for a given study sample would reflect this aspect as well. However, it averages the net benefit and may not be observed in all patients (90%) as other walking limiting factors, e.g. coronary artery disease, joint replacements, may co-exist. TLR rates are equally important (RRV=90%) and have been used for Markov-state transition model inputs for coronary devices by the National Institute for Health and Clinical Excellence (NICE) in the UK. 25 ABI measurements (RRV=75.0%) correlate well with clinical benefit. Nevertheless, other patho-physiological or methodological confounding factors 26 may hinder the detection of direct correlation between ABI and the true post-procedural benefit from a QOL seem to be an appropriate endpoint. Finally, the theoretical basis provided by the Navier-Stokes equation 30 , which establishes also a length effect on narrowing fluid boundaries in the most general form, should not be ignored.
ABI measurements
Al-Qaisi et al. 26 gave a comprehensive overview of ABI measurements and their practical value in diagnosing PAOD in patients with various co-morbidities. A plethora of studies have been published on this topic but two potential sources of misleading readings may compromise the prognostic value of ABI measurements. First of all, collateral vasculatures bypassing peripheral lesions may still be able to propagate pressure pulses to the ankle, thereby leading to normal ABI values. In such cases, the authors conclude that ABI cannot reveal the culprit lesion. Furthermore, Al-Qaisi and coworkers point out that strongly calcified peripheral arteries could lead to higher than expected pressure wave amplitudes due to the media sclerosis. This, in turn, would also lead to misleading ABI measurements. Patient with strongly calcified arteries include primarily diabetics, patients with renal insufficiency, designing a study protocol, one refers to prior studies with similar target populations and treatments. Subsequently, an affordable sample size is determined, which is pivotal to the trial's cost-efficacy in company sponsored trials. Just because an endpoint is easily measured and requires a reasonable sample size, it does not automatically reflect patient benefits or improvement in QOL. In the remainder of this discussion, we would like to focus on some endpoints which do not appear to be appropriate from a reimbursement standpoint
Angiographic endpoints
Despite being a direct outcome of quantitative angiography, we would like to advise to exercise caution when using MLD as a primary endpoint. In our opinion, MLD seems to be hemodynamically indifferent (Figure 10 ) since it does not consider the length of stenosis, as pointed out by studies in the field of interventional cardiology. 23 This, may have a significant impact on the pressure drop across the stenosis, affecting the magnitude of ischemia distal to the stenotic lesion, as shown in coronary lesions by Brosh and coworkers. 28 Despite the fact that the value of MLD is recognized and has been verified by in-vivo animal studies 29 , MLD does not 
Reimbursement scoring system
To our knowledge, the proposed scoring system is the first attempt to illustrate study population sizes and reimbursement values for a given set of relevant cardiovascular trial endpoints. Although this scoring system is semi-subjective, we still believe that it serves its purpose for early trial design and satisfies reimbursement needs. The fact that WD and ABI seem to be the most useful endpoints is in agreement with a prior NICE technology appraisal for vaso-active drug treatments in patients with PAOD.
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LIMITATIONS
Even though we estimated the required patient numbers for specific study scenarios, this work does not replace a properly conducted sample size estimation for a given design. This reimbursement scoring system needs to be critically assessed and improved. Furthermore, WD and ABI, as the preferred endpoints, require proper inclusion and exclusion criteria to minimize loss to follow-up and other relevant factors that are not related to the treated limb.
CONCLUSIONS
The primary endpoints of WD and ABI offer the best reimbursement value for a relatively small study sample given that other non-vascular walking limitations can be controlled. Angiographic endpoints such as MLD do not seem useful from a reimbursement standpoint despite their intuitiveness.
and elderly patients who represent a significant proportion of patients with PAOD.
Walking distance
From a quality of life standpoint, walking distance should be a preferred endpoint. However, it must be pointed out that due to factors unrelated to the affected limb, such as coronary artery or pulmonary disease, the proportion of patients lost to follow-up may be quite high, which precludes repeated measurements. Matsumura et al. 31 investigated the efficacy of stent implantations in the superficial femoral artery. In that study, the investigators reported that only 10% of all patients were available to determine their walking distance at a one-year follow-up.
Follow-up interval
Confounding factors during the follow-up period may hinder the detection of the real treatment effect in a properly conducted trial. A well-designed and sufficiently powered study might fail when the primary endpoint is not reached at follow-up. Obviously, throughout the period between hospital discharge and follow-up, confounding factors may preclude the determination of the cause-effect relationship between the initial treatment and the primary outcome ( Figure  11 ). Factors like physical exercise or non-compliance to co-medication are also known to affect the outcome. In a randomized trial, one must assume that these biases are equally distributed across treatment groups. There is a lot of studies that elucidate interactive effects, such as the influence of social support on co-medication compliance. 32 These may also be applicable in the follow-up period. We think that this potential bias may be quite challenging in smaller patient groups of less than 100 subjects.
